[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"mahenoor alaa eldeen naem\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100564265",false,"NCT06626932","Implications of Biological and Procedural Factors of 18-f FDG Uptake by Normal Organs and Neoplastic Lesions","Implications of Biological and Procedural Factors of 18-f FDG PET\u002FCT Uptake by Normal Organs and Neoplastic Lesions","Inclusion Criteria:\n\n* cancer patients referred to nuclear medicine unit\n\nExclusion Criteria:\n\n* patients with increased FDG uptake associated with non malignant causes such as diffuse bone marrow FDG uptake or lung infection or patients with extensive metastasis in target organs","ALL","1 Year","90 Years",{"count":19,"type":20},259,"ESTIMATED","OBSERVATIONAL","To evaluate implications of biological and procedural factors of 18-f FDG PET\u002FCT uptake on normal organs and neoplastic lesions.",[24],"Oncologic Diseases",[26],"18-f FDG PET\u002FCT","NOT_YET_RECRUITING","2024-10-02",{"date":30,"type":31},"2024-10-04","ACTUAL",{"date":33,"type":20},"2024-10",{"date":35,"type":20},"2026-11",{"name":37,"class":38},"mahenoor alaa eldeen naem","OTHER",""]